In a significant strategic move, Emcure Pharmaceuticals Ltd. has announced that its Board of Directors has approved the acquisition of the remaining minority stake in its subsidiary, Zuventus Healthcare Ltd. With this transaction, Zuventus will become a wholly owned subsidiary of Emcure, strengthening the company’s presence and control in the domestic pharmaceutical market.
The transaction is expected to be completed in Q2 of FY 2026, subject to the necessary closing conditions. According to the company, this acquisition marks a key milestone in Emcure’s growth roadmap and aligns with its strategic focus on consolidating its domestic market footprint.
